Rule 2026-17536

Effective first, comments after — where the statute itself has authorized the shortcut

Department of Justice ・Published Aug 27, 2026 ・91 FR 55259

The Drug Enforcement Administration placed a newly approved general anesthetic into Schedule IV of the Controlled Substances Act by interim final rule, effective immediately. This is a category where the statute waives the showing of good cause ordinarily required.

Document overview (primary data)

  • Document typeRule
  • AgencyDepartment of Justice
  • Citation91 FR 55259

Key points

  • The Drug Enforcement Administration placed a newly approved general anesthetic in Schedule IV by interim final rule, effective the same day.
  • The substance was approved by the Food and Drug Administration on May 29, 2026 for induction of general anesthesia in adults.
  • The provision relied on permits an interim final rule without requiring the agency to demonstrate good cause.
  • Its purpose is to speed scheduling so newly approved drugs may be marketed without undue delay following approval.
  • Comment and hearing rights remain, with both deadlines falling on September 28, 2026.

1DEA places the general anesthetic cipepofol in Schedule IV by an interim final rule, effective immediately

On August 27, 2026 the Drug Enforcement Administration published an interim final rule placing cipepofol, a general anesthetic, in Schedule IV of the Controlled Substances Act, effective the same day (DEA 1713).

The Food and Drug Administration approved the new drug application for cipepofol on May 29, 2026, for induction of general anesthesia in adults undergoing surgery, and the Department of Health and Human Services recommended Schedule IV. Section 811(j) of the Act provides this faster path so that newly approved drugs can be marketed without undue delay after approval. Comments and hearing requests were due by September 28, 2026.

2Reversing the order

A rule ordinarily takes effect after a proposal and a comment period. An interim final rule reverses that: it takes effect first and comments follow, so that what is commented on is already in force. That makes it exceptional. Why is it permitted? This case gives a clear answer.

3Without scheduling, it cannot be sold

  1. 1May 29, 2026The Food and Drug Administration approves a new drug application for induction of general anesthesia
  2. 2RecommendationThe Department of Health and Human Services recommends placement in Schedule IV
  3. 3August 27, 2026 (this rule)An interim final rule takes effect the same day, placing the substance in Schedule IV
  4. 4By September 28, 2026Comments and requests for a hearing are accepted

A medicine that is a controlled substance cannot be distributed until it is scheduled. If approval is granted while scheduling drags, patients wait longer for access. The shortcut here therefore exists not to relax regulation but to avoid delaying an approved medicine.

4Two kinds of shortcut

Where the agency finds good causeWhere the statute has waived it in advance (this case)
The agency shows ordinary procedure is impracticable or the likeThe statute provides that no such showing is required
Judged on the circumstances of each caseApplies uniformly to a defined category
Covers cases such as the temporary safety zones this site also holdsCovers scheduling of newly approved drugs

Skipping ordinary procedure normally requires the agency to give its reasons. The provision relied on here, though, does not require the agency to demonstrate good cause. Effective-first rules thus divide into those resting on an agency finding and those for which the statute has already cleared a path.

5Comment and hearing remain

Shortening the procedure did not remove the opportunity to comment or to request a hearing, both due September 28, 2026. A hearing request must come with a written statement of position on the matters of fact and law asserted. Taking effect first and closing off objection are treated as separate things.

6What Schedule IV signifies

The Controlled Substances Act sets schedules I through V according to abuse potential and medical use. Schedule IV covers substances with accepted medical use and comparatively lower potential for abuse — a placement consistent with a general anesthetic administered in medical settings.

Why it matters

A procedural shortcut exists to avoid delaying an approved medicine rather than to relax regulation. Shortcuts rest either on an agency finding or on a statutory category, and the basis determines how heavy the procedure is.

FAQ

What is an interim final rule?
A rule that takes effect before comments are sought, so that what is commented on is already in force. It is an exceptional procedure.
Why may the procedure be shortened?
Here the statute permits it without a showing of good cause, because an approved medicine that is a controlled substance cannot be distributed until it is scheduled.

Sources (primary)

Source: Federal Register (federal documents, public domain). Links go to the official site.

#DEA#Controlled substances#Interim final rules#Drug approval#Justice
Disclaimer: This site independently summarizes and classifies information based on official data sources. Always verify the latest and accurate information with the official sources. Content on finance, health, legal, and security is information, not advice. This site is not an official website of the U.S. government.